MelanotanII, Melanocortin receptor 3 and 4 agonist, administered intraperitoneally displayed potent effects against spasms in the prenatally primed model of cryptogenic Infantile Spasms (cIS). To confirm the central effects of melanotanII and to understand its true potential as an anti-epileptic drug for Infantile Spasms in humans, a different route of administration was tested in this experiment. The route of intranasal administration which is less stressful then IP and prevents the peripheral effects seen in drugs like ACTH (the first line drug for cIS) was utilized. Due to its small size (ten amino acids) melanotanII was delivered intranasally and tested for its effect against spasms in prenatally betamethasone-primed animals. A concentration of 10mg of melanotanII in 6ml was administered through nostrils (3ml per nostril) in 15 days old rats. Control animals received saline instead of melanotanII. Collected data did not yield significant differences between intranasally melanotanII - and saline-delivered groups.

Different route of administration for melanocortin receptor agonist, melanotan II, in the model of cryptogenic infantile spasms

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.